AbbVie (NYSE:ABBV) announced on Thursday that the company has reached settlements with all generic drugmakers to resolve ...

The biopharmaceutical company doesn’t expect U.S. generic entry for the drug before 2037 now that it has settled litigation.

Penn researchers say they will pursue larger-scale studies to continue testing whether hydroxychloroquine and everolimus can ...

Rapamycin is an immune suppressant often used in organ transplant patients, but it has also been shown to extend life in ...

Biocon CEO Siddharth Mittal reveals plans to launch generic versions of diabetes drug Ozempic in key markets by the end of ...

The news that the brand is protected from generics for more than a decade "gives AbbVie a kind of tremendous runway," to sell ...

One of the great triumphs of health policy is America’s generic drug market. Nine out of ten U.S. prescriptions are filled with generics. That overwhelming share saves patients and taxpayers hundreds ...

President Donald Trump has plastered taxes on products from almost every country on earth. He’s targeted specific imports, ...

Gary Rieschel, a founding managing partner of Shanghai-based Qiming Venture Partners, said that the gap between China and the United States in the development of first-in-class drugs has narrowed from ...

While 2025 began on a positive note for the pharmaceutical industry, things have taken a sharp turn amid escalating fears of a global trade war. While Trump had initially exempted pharmaceuticals from ...

Zydus Lifesciences’ subsidiary ZyVet Animal Health has launched FDA-approved generics for urinary incontinence ...